Trial Profile

A Randomized, Controlled, Multicenter, Parallel-Group Phase IIa Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Severe COVID-19

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emiplacel (Primary)
Indications COVID-19 pneumonia; COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Sponsors Pluri

Most Recent Events

09 Oct 2023 Status changed from active, no longer recruiting to discontinued.
25 Apr 2023 This trial has been completed in Bulgaria (global end date: 2022-06-15), according to European Clinical Trials Database.
13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com